FLT180a
Phase 2- Indications
- Hemophilia B
Company intelligence / Profile preview
Freeline Therapeutics
Stevenage, United Kingdomfreeline.life ↗
- Ownership
- Public · FRLN
- Employees
- ~57
- Development stage
- Phase 2
01
Overview
Freeline has advanced multiple AAV-based gene therapies into Phase 1/2 trials. FLT180a for hemophilia B has shown promising results in early studies. FLT190 for Fabry disease and FLT201 for Gaucher disease type 1 are also in Phase 1/2 trials. The company aims to provide one-time curative treatments by delivering functional copies of therapeutic genes to the liver using its proprietary platform.
- Therapeutic areas
- HematologyRare Diseases
- Modalities
- Gene therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Freeline Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Freeline Therapeutics.